The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Working now
Anyone else see 'this video is private'?
Encouraging news imo.
A big pharma buy in via a JV would be better still.
JuvLife partnership around the application of the Sulforadex® technology continues to progress well; US market launch of a JuvLife nutritional health product is anticipated around end- 2023They seem to be pushing this further and further down the road. I'm sure when it was first announced the payment was due in 2022.
Results out today. Sufficient cash to last the two years it is going to take to see if SFX-01 actually works? Might be worth a punt on a two year hold basis if you can buy around 3.25p in the next few weeks. Unfortunately I bought shares for around 8p.
Few chunky buys today.
Sorry to hear that radar. Hope things improve for you soon.
Whew are the buyers, rather a sad and lonely place here with one direction.
Buyers about
Question is when will we hit zero ?
All well and good, but still not a peep on the significant developments we were led to expect on the two clinical trials.
Come on Huw, update your shareholders ffs you taciturn b*st*ard.
easyp - any advisor worth his salt would have kept kight well away from this stock. Like the majority of pharma companies in this field the odds are more in favour of them disappearing into oblivion than becoming a major success. They've been around for a long time, have promised the earth and delivered nothing, unless of course your a board member in which case you've done very nicely.
I take a strange comfort from knowing that if this all comes to nothing Kight will have lost more than me. The other side of the coin is that possibly Mr Kight has good advisors who having done due diligence believe EVG can produce something of value. Then again I thought that about SENS and got badly burned.
Tekcapital have made a good recovery though over the last two years. 4p to 33p and rising . Things could change here rapidly also with a bit of good news.
dannatt - I would hardly call him shrewd, he is currently sitting on an approximate 50% loss.
Only reason these go up is when he steps in to top up, otherwise it's a steady decline.
I hope Evgen does the same as Tekcapital where Kight is also invested. Looks like a very shrewd investor.Good to have him on board.
So that’s over one hundred thousand pounds worth purchased. Where have these shares come from.No large share trades reported in the last week.Has he bought them off market from someone else or is the trade still to be reported. Very strange !!
Another 1% accumulated on the quiet.
c.$10m in milestone payments to come from Juvenescence, some of which you would expect to be payable on product launch. In addition to this royalties (rate not specified) will be payable on sales.
In the meantime we are due news on the commencement/progress of two clinical trials - the Phase 1/PK study on the new 'tablet' formulation of SFX-01 and the Phase 2 glioblastoma trial.
Presentation from Greg Bailey the CEO of Juvenescence at the Master Investor show last month:
Https://www.youtube.com/watch?v=SJ6UT0Kj62w
Confirms their sulforaphane based nutraceutical product "Crucif Boost" (which as we know is based on technology licenced from EVG) is on track for launch H1 next year.
meanwhile yesterday's pump is today's dump. That's AIM
There seems to be a lot of 50-100k trades plus a number of large chunks being bought in the last couple of days, so doubt this is punter money but who knows.
Agree with you though on the management point of not buying in with their own money not inspiring long term confidence. For me though I still think it's massively oversold and so presents a good opportunity to average down and derisk at some point of time in the short or medium term once it reaches a decent fair value market cap of £20-30m which is where I would put it given the significant cash value.
Just be a bit weary, this is an extremely Leakey ship when it comes to info, shareholders seem to be the last to know anything so there could be some imminent news on the other hand Market makers also generate some excitement enticing new punters onboard to off load their positions. Until the board actively start buying I'm sticking with the later probability.